Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine.

作者: Venkata Kolli , Kevin Denton , Dileep Borra , Madhuri Pulluri , Ashish Sharma

DOI: 10.1002/PON.3209

关键词: Granulocyte colony-stimulating factorInternal medicineRituximabOncologyImmunologyVincristineClozapineAdverse effectCyclophosphamideFilgrastimMedicineChemotherapy

摘要: Background Clozapine is reserved for overcoming treatment resistance in schizophrenia. Malignancy common schizophrenia; however, there limited evidence available on continuing clozapine with chemotherapy, both having hematological adverse effects. Objective To report a case the use of granulocyte colony-stimulating factor (G-CSF) conjunction and chemotherapy. Methods We searched PubMed any information G-CSF chemotherapy. We patient schizophrenia who developed B-cell lymphoma was treated chemotherapy consisting CHOP regimen, rituximab, methotrexate. He continued G-CSF. Results We did not find reports found series rechallenge clozapine-induced agranulocytosis mixed results. In our clozapine, white blood cell counts reduced by were successfully replenished filgrastim, G-CSF. Conclusions With risks psychosis relapse exacerbation discontinuing addition could be useful aid replenishing lost to whilst clozapine. However, further study needed this combination. Copyright © 2012 John Wiley & Sons, Ltd.

参考文章(13)
David G. Maloney, Antonio J. Grillo-López, Christine A. White, David Bodkin, Russell J. Schilder, James A. Neidhart, Nalini Janakiraman, Kenneth A. Foon, Tina-Marie Liles, Brian K. Dallaire, Ken Wey, Ivor Royston, Thomas Davis, Ronald Levy, IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Blood. ,vol. 90, pp. 2188- 2195 ,(1997) , 10.1182/BLOOD.V90.6.2188
Dominic P Williams, Munir Pirmohamed, Dean J Naisbitt, James L Maggs, B Kevin Park, None, Neutrophil Cytotoxicity of the Chemically Reactive Metabolite(s) of Clozapine: Possible Role in Agranulocytosis Journal of Pharmacology and Experimental Therapeutics. ,vol. 283, pp. 1375- 1382 ,(1997)
Tiziana Frieri, Giulio Barzega, Alessandra Badà, Vincenzo Villari, Maintaining clozapine treatment during chemotherapy for non-Hodgkin's lymphoma. Progress in Neuro-psychopharmacology & Biological Psychiatry. ,vol. 32, pp. 1611- 1612 ,(2008) , 10.1016/J.PNPBP.2008.05.017
Karine Goulet, Sylvain Grignon, Case report: clozapine given in the context of chemotherapy for lung cancer Psycho-oncology. ,vol. 17, pp. 512- 516 ,(2008) , 10.1002/PON.1267
Eric Tran, Frédéric Rouillon, Jean-Yves Loze, Françoise Casadebaig, Alain Philippe, Fabien Vitry, Frédéric Limosin, Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer. ,vol. 115, pp. 3555- 3562 ,(2009) , 10.1002/CNCR.24383
Staffan Hägg, Staffan Rosenius, Olav Spigset, Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. International Clinical Psychopharmacology. ,vol. 18, pp. 173- 174 ,(2003) , 10.1097/01.YIC.0000062800.74434.6C
GRIGORI JOFFE, SAANA ESKELINEN, EILA SAILAS, Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia/agranulocytosis. American Journal of Psychiatry. ,vol. 166, pp. 236- 236 ,(2009) , 10.1176/APPI.AJP.2008.08081295
Louisa R. Dunk, Linda J. Annan, Christopher D. Andrews, Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. British Journal of Psychiatry. ,vol. 188, pp. 255- 263 ,(2006) , 10.1192/BJP.188.3.255
B. Sperner-Unterweger, I. Czeipek, S. Gaggl, D. Geissler, G. Spiel, W. W. Fleischhacker, Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine. British Journal of Psychiatry. ,vol. 172, pp. 82- 84 ,(1998) , 10.1192/BJP.172.1.82